Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and Type 2 diabetes? Results from the WELCOME study

Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and Type 2 diabetes? Results from the WELCOME study

Bibliographic Details
Main Authors:	Scorletti, E, Bhatia, B, McCormick, K, Clough, G, Nash, K, Hodson, L, Calder, P, Byrne, C
Format:	Journal article
Published:	2014

Similar Items

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
by: Scorletti, E, et al.
Published: (2014)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
by: Li Rong, et al.
Published: (2023-01-01)

The importance of the fatty acid transporter L-carnitine in non-alcoholic fatty liver disease (NAFLD)
by: Savic, D, et al.
Published: (2020)

The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Dragana Savic, et al.
Published: (2020-07-01)

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
by: Hodson, L, et al.
Published: (2017)

Whole-body and hepatic dietary fatty acid oxidation is related to postprandial insulin concentrations in people with non-alcoholic fatty liver disease with varying degrees of insulin resistance
by: Hodson, L, et al.
Published: (2013)

Effect of Omega‐3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD
by: Václav Šmíd, et al.
Published: (2022-06-01)

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Marcin Kosmalski, et al.
Published: (2023-02-01)

Probiotics as Potential Therapy in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Margalida Monserrat-Mesquida, et al.
Published: (2023-04-01)

Splanchnic balance of free fatty acids, endocannabinoids and lipids in subjects with NAFLD
by: Kotronen, A, et al.
Published: (2010)

Symposium 20: Pharmacological treatment of the patient with Non-Alcoholic Fatty Disease (NAFLD)
by: Karina Fuentes
Published: (2022-09-01)

Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis
by: Andrea Caddeo, et al.
Published: (2023-02-01)

Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment
by: Xiangyu Guo, et al.
Published: (2022-12-01)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress
by: Sue Shea, et al.
Published: (2021-11-01)

The Effect of Interval Training and Omega-3 on Mitochondrial Biogenesis in the Liver Tissue of Nonalcoholic Fatty Liver Disease (NAFLD)Rats
by: M Kazemi, et al.
Published: (2023-09-01)

Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis
by: Vicneswarry Dorairaj, et al.
Published: (2021-12-01)

Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Marcin Kosmalski, et al.
Published: (2022-09-01)

Nutritional Management in Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Sepideh Mahboobi, et al.
Published: (2015-07-01)

Nonalcoholic fatty liver disease (NAFLD) among older adults
by: Panyavee Pitisuttithum, et al.
Published: (2022-12-01)

Gut-liver axis in nonalcoholic fatty liver disease (NAFLD)
by: Koo, Yolanda Wei Ling
Published: (2023)

Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
by: Francesca Fianchi, et al.
Published: (2021-06-01)

Treatments for NAFLD: State of Art
by: Alessandro Mantovani, et al.
Published: (2021-02-01)

NAFLD: Mechanisms, Treatments, and Biomarkers
by: Fatiha Nassir
Published: (2022-06-01)

Comparison of non-alcoholic fatty liver disease (NAFLD) model using diet-induced NAFLD mice with genetically modified mice
by: Mohd Danial Mohd Efendy Goon,, et al.
Published: (2022)

Allium sativum: A potential natural compound for NAFLD prevention and treatment
by: Parham Mardi, et al.
Published: (2023-02-01)

Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
by: David Carneros, et al.
Published: (2020-11-01)

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
by: Agostino Di Ciaula, et al.
Published: (2021-05-01)

Dietary consumption and serum pattern of bioactive fatty acids in NAFLD patients
by: Fabiola López-Bautista, et al.
Published: (2020-09-01)

Effect of mediterranean diet on non-alcoholic fatty liver disease (NAFLD)
by: Patrycja Walczak, et al.
Published: (2023-01-01)

Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy
by: Suneth Buddhika Agampodi, et al.
Published: (2022-12-01)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
by: Hannah K. Drescher, et al.
Published: (2019-08-01)

Fecal Microbiota Transplantation in NAFLD Treatment
by: Ludovico Abenavoli, et al.
Published: (2022-10-01)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review
by: Paulina Głuszyńska, et al.
Published: (2021-12-01)

From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease
by: Mary E. Rinella, et al.
Published: (2024-01-01)

Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD)
by: Adnan Khan, et al.
Published: (2022-10-01)

Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
by: Pengyu Yao, et al.
Published: (2022-12-01)

Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
by: Saumya Madushani Samarasinghe, et al.
Published: (2023-08-01)

The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Dominika Maciejewska-Markiewicz, et al.
Published: (2021-06-01)

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences
by: Armando Tripodi, et al.
Published: (2022-01-01)

The effect of Ramadan fasting on non-alcoholic fatty liver disease (NAFLD) patients
by: Seyed Mostafa Arabi, et al.
Published: (2015-06-01)